1-20 of 45
Jun Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Analysis of 15 Cases of Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Post-Transplant Treated with CART Combined with Radiotherapy

Ruyue Zheng, Hong Yan, Biyi Li, Yuehui Lin, Shuangyou Liu, Lihong An, Biping Deng, Jun Zhang, Chunrong Tong, Tong Wu, Defeng Zhao
Journal: Blood
Blood (2024) 144 (Supplement 1): 7212.
https://doi.org/10.1182/blood-2024-204574
Published: 2024
Journal Articles

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hui-Peng Lee, Stephen S. Opat, John Hrom, David Kliman, Paula Marlton, Peng Liu, Chenmu Du, Amber Lussier, Jun Zhang, Haiyi Guo, Steven P. Treon
Journal: Blood
Blood (2024) 144 (Supplement 1): 1661.1.
https://doi.org/10.1182/blood-2024-198728
Published: 2024
Journal Articles

Application of 18F-Fapi PET/MRI in the Assessment of Myelofibrosis: A Multi-Center Prospective Observational Study

Dan Tian, Jun Zhang, Yuanyuan Zhu, Weijia Huang, Jin Zhang, He Huang, Xinhui Su, Jie Sun
Journal: Blood
Blood (2024) 144 (Supplement 1): 3599.
https://doi.org/10.1182/blood-2024-207873
Published: 2024
Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani
Journal: Blood
Blood (2021) 138 (Supplement 1): 2576.
https://doi.org/10.1182/blood-2021-147618
Published: 2021
Journal Articles

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Nicola Vianelli, Giulia Benevolo, Alessandro Vannucchi, Claire N. Harrison, Michael Loschi, Haifa Kathrin Al-Ali, Massimiliano Bonifacio, Francisco Cervantes, Tomasz Wrobel, Giovanni Barosi, Jean-Jaques Kiladjian, Srdan Verstovsek, Ruben A. Mesa, Shelonitda Rose, Vishwanath Gharpure, Christopher Hernandez, Jun Zhang, Francesco Passamonti
Journal: Blood
Blood (2021) 138 (Supplement 1): 3643.
https://doi.org/10.1182/blood-2021-147614
Published: 2021
Journal Articles

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Tamas Masszi, MD, Elena Mishchenko, MD, Mark W. Drummond, PhD FRCPath, Eric Jourdan, MD, Alessandro M. Vannucchi, MD, Mindaugas Jurgutis, Vincent Ribrag, MD, Alessandro Rambaldi, MD PhD, Liang Piu Koh, MBBS, MRCP, Shelonitda Rose, MD, Jun Zhang, PhD, Claire Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 10–12.
https://doi.org/10.1182/blood-2020-137279
Published: 2020
Journal Articles

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Amy S. Ruppert, PhD, Levi D. Pederson, MS, Michael V. Knopp, MD PhD, David Poon, BS, Jun Zhang, PhD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD MSSc, Lawrence H. Schwartz, MD, Wyndham H. Wilson, MD PhD, John P. Leonard, MD, Nancy L. Bartlett, MD, Heiko Schöder, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50.
https://doi.org/10.1182/blood-2020-139979
Published: 2020
Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Clinical Trials & Observations
Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett
Journal: Blood
Blood (2020) 135 (25): 2224–2234.
https://doi.org/10.1182/blood.2019003277
Published: 2020
Includes: Supplemental data
Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Jun Long, Ming-Yuan Jia, Wei-Yue Fang, Xin-Jie Chen, Li-Li Mu, Zhong-Yu Wang, Yan Shen, Ru-Fang Xiang, Li-Ning Wang, Ling Wang, Chuan-He Jiang, Jie-Ling Jiang, Wen-Jun Zhang, Yi-Dan Sun, Li Chang, Wen-Hui Gao, Ying Wang, Jun-Min Li, Deng-Li Hong, Ai-Bin Liang, Jiong Hu
Journal: Blood
Blood (2020) 135 (17): 1472–1483.
https://doi.org/10.1182/blood.2019003538
Published: 2020
Includes: Supplemental data
Journal Articles

Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ

Lei Zhang, Jing Li, Hui Xu, Xianyu Shao, Li Fu, Ye Hou, Caiqing Hao, Wenyan Li, Kanak Joshi, Wei Wei, Yan Xu, Feng Zhang, Shaojun Dai, Peter Breslin, Jiwang Zhang, Jun Zhang
Journal: Blood
Blood (2020) 135 (14): 1133–1145.
https://doi.org/10.1182/blood.2019001863
Published: 2020
Includes: Supplemental data
Journal Articles

Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, MD PhD, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Jun Zhang, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 668.
https://doi.org/10.1182/blood-2019-129288
Published: 2019
Journal Articles

Ripk3 Signaling Regulates Hematopoietic Stem Cell Number and Function during Stress

Lei Zhang, PhD, Huacheng Luo, PhD, Jing Li, Hong-Min Ni, Mark Sellin, Feng Zhang, Jun Zhang, Peter Breslin, PhD, Wei Wei, William Small, Jr., Wen-Xin Ding, Suming Huang, PhD, Jiwang Zhang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3714.
https://doi.org/10.1182/blood-2019-131332
Published: 2019
Journal Articles

Novel Antibodies Against Glycoprotein Ibα Inhibit Pulmonary Metastasis By Affecting Vwf-Gpibα Interaction

Qi Yingxue, Wenchun Chen, PhD, Ke Xu, Fengying Wu, Xuemei Fan, Shengxiang Ren, Junling Liu, Wei Deng, PhD, Jun Zhang, Renhao Li, PhD, Jianwen Liu, Xin Liang, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1133.
https://doi.org/10.1182/blood-2018-99-117613
Published: 2018
Journal Articles

B-cell receptor–mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma

Li Li, Jun Zhang, Juan Chen, Zijun Y. Xu-Monette, Yi Miao, Min Xiao, Ken H. Young, Sa Wang, L. Jeffrey Medeiros, Michael Wang, Richard J. Ford, Lan V. Pham
Journal: Blood
Blood (2018) 132 (17): 1805–1817.
https://doi.org/10.1182/blood-2018-03-841015
Published: 2018
Includes: Supplemental data
Journal Articles

PD-L1 Expression and Gene Amplification in CD30+ Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics

George Rassidakis, MD PhD, Yi Miao, MD PhD, Jun Zhang, MD, Vassilis Atsaves, PhD, Lorand Kis, MD PhD, Karin E Smedby, MD PhD, Yong Li, PhD, Zijun Yidan Xu-Monette, PhD, Ken H. Young, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1475.
https://doi.org/10.1182/blood.V130.Suppl_1.1475.1475
Published: 2017
Journal Articles

Pharmacodynamic Study of Copanlisib in Patients with Non-Hodgkin's Lymphoma and Advanced Solid Tumors: Confirmation of on-Target PI3K Inhibitory Activity

Franck Morschhauser, MD PhD, Ahmad Awada, MD PhD, Jean-Pascal Machiels, MD PhD, Gilles Andre Salles, MD PhD, Sylvie Rottey, MD PhD, Simon Rule, MD, David Cunningham, MD FRCP, Frederic Peyrade, MD, Christophe Fruchart, MD, Hendrik-Tobias Arkenau, MD PhD, Isabelle Genvresse, MD, Li Liu, PhD, Christoph Kneip, PhD, Carol Pena, PhD, Joachim Grevel, PhD, Jun Zhang, PhD, Galia Cisternas, PhD, Susanne Reschke, MSc, Camille Granvil, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1256.
https://doi.org/10.1182/blood.V130.Suppl_1.1256.1256
Published: 2017
Journal Articles

Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Clinical Trials & Observations
Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young
Journal: Blood
Blood (2017) 129 (12): 1658–1668.
https://doi.org/10.1182/blood-2016-11-748855
Published: 2017
Journal Articles

Correlation Between Tumor Microenvironment and the Inflammatory Factors in Lymphoma-Burdened Mice

Jun Zhang, Jun Ni, Pei Xu, Qingqing Shi, Jian Gu, Wu Depei, MD
Journal: Blood
Blood (2015) 126 (23): 5133.
https://doi.org/10.1182/blood.V126.23.5133.5133
Published: 2015
Journal Articles

Blocking TNF and IL-1 Sensitizes AML Stem Cells to NF-κB Inhibitor Treatment

Volk Andrew, Jing Li, Jun Zhang, PhD, Joseph Cannova, Caiqin Hao, Chenglong Hu, Jiewen Sun, Yan Xu, Wei Wei, Peter Breslin, PhD, Jianjun Chen, PhD, Jiwang Zhang, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2302.
https://doi.org/10.1182/blood.V124.21.2302.2302
Published: 2014
Journal Articles

Effectiveness of First and Second Line Nilotinib in Chronic Myeloid Leukemia (CML) Patients with Atypical e1a2 BCR-ABL Transcripts

Xiaomin Gui, Jinlan Pan, Huiying Qiu, Jiannong Cen, Yongquan Xue, Suning Chen, MD PhD, Jun He, Hongjie Shen, Li Yao, Jun Zhang, Yafang Wu, Wu Depei, MD
Journal: Blood
Blood (2014) 124 (21): 5520.
https://doi.org/10.1182/blood.V124.21.5520.5520
Published: 2014